Empowering Public Health Across the CIS Region

Nation-Wide Study Confirms ChilRun full Accelerates Growth and Development in Children, in just 90 days

Guardians of Global Health: Leading Vaccine Innovators of 2025

Press Release - DFC Commits US$20 Million Long-Term Loan to Panacea Biotec Towards Capacity-Expansion Project for Hexavalent Vaccine

Press Release - Initiation of Phase III Clinical Trial of DengiAll by ICMR and Panacea Biotec

Panacea Biotec launches EasyFourPol® in India and receives registration of Valganciclovir Powder for Oral Solution in Germany

US delegation led by Ambassador to India - Eric Garcetti, Assistant Secretary for Global Affairs, HHS - Loyce Pace and HHS Health Attaché Genessa Giorgi visited Panacea Biotec R&D Centre - Developing Novel Tetravalent Dengue Vaccine “DengiAll”

Panacea Biotec donates 125,000 doses of Easyfive-TT (DTwP-HepB-Hib) a fully liquid Pentavalent vaccine to Ministry of Health, Republic of Cuba for use in the National Health System

Panacea Biotec receives UNICEF & PAHO awards for supply of Pentavalent Vaccine (DTwP-HepB-Hib)

Panacea Biotec divests Domestic Pharmaceutical Formulation Brands for India and Nepal